One child dies every two minutes from malaria. Wider use of a new vaccine can make a dent in that devastating statistic. The World Health Organization recommends the vaccine for broad use in sub-Saharan Africa and other areas with moderate to high malaria transmission, after years of studies in some 900,000 children showed it to be safe and effective. But despite this widely hailed breakthrough, the malaria vaccine hasn’t been met with the enthusiasm we think it deserves. Some big players, like the Bill and Melinda Gates Foundation and the Global Fund — donors we admire and partner with on several projects — have lamented the vaccine’s relatively low reduction in severe malaria when used alone and say it costs too much, despite the clear cost-benefits and efficacy synergies the WHO demonstrated when piloting the vaccine in real-world contexts. View More